SARS-CoV-2 POC Antigen Test
Specifications
Test Procedure
Additional Information
To Order
SARS-CoV-2 POC Antigen Test
What are the differences between antigen, PCR, and antibody testing?
i-ImmunDx™ Analyzer
CoVisAg

CoVisAg is a rapid diagnostic test for the qualitative detection of SARS-CoV-2 antigens in nasopharyngeal and oropharyngeal swab samples. Results are available within 15 to 30 minutes of sample collection, and can be visually interpreted by eye or using the
i-ImmunDx™ Analyzer.

CoVisAg relies on advanced double-sandwiched antibody lateral flow and colored nano-particle technology to enhance sensitivity and precision.

Point-of-care (POC) test that can be used directly at the patient’s side

Easy to perform, no additional equipment required

Suitable for early virus detection

Specifications
Available in 2 variations: for the nucleocapsid (N) protein and spike (S) protein.
1 box (50 tests) includes: Quantity
CoVisAg Test Card 50
Reaction Buffer 50
Sterile Flocked Swabs 50
Disposable Pipettes 55
Positive and Negative Controls 1 each
Positive and Negative Control Buffers 1 each
Test Procedure

Get Results in 5 Simple Steps:

Additional Information
  • How does antigen testing compare with PCR testing?
    RT-PCR Nucleic Acid Tests

    Time-consuming and complex: The test procedure and sample processing required for most PCR tests are labor-intensive and require specialized equipment and well-trained personnel.

    Limited flexibility: PCR testing is primarily performed in a laboratory setting, meaning samples must be transported to adequate facilities and the time-to-results is delayed.

    Expensive equipment: PCR equipment can be costly, which means it is less accessible, especially for communities that are already limited in resources and infrastructure.

    Nucleic acid is extremely sensitive and unstable: For most PCR tests, accurate results are rely on the nucleic acid remaining intact. Transportation and handling of samples increases the risk of sample degradation, which leads to inaccurate results. 

    Compared with PCR testing, antigen tests can offer a better pathway to implementing widespread testing by:

    Removing time-consuming and labor-intensive sample processing during the test procedure, lowering the chances of user error to get faster, more reliable results;

    Eliminating the need for specialized equipment or trained personnel, while reducing the labor costs, making testing more accessible for all;

    Relieving the pressure off of hospitals and care centers, which are already working overcapacity, by moving testing to the site of sample collection, or other locations.

    Simple, equipment-free antigen tests like CoVisAg offer fast, portable testing and deliver results within 30 minutes of sample collection.

    CoVisAg requires no additional equipment, meaning that tests can be performed directly at the point of collection or at the patient’s side. It also reduces the time and labor costs for testing as well as the delays for getting results back, making it the most suitable test method for implementing widespread testing.

  • How does antigen testing compare with antibody testing?

    Antibody tests, also known as serology tests, help assess if someone has previously been infected, which can be helpful in determining who may have immunity to the virus.

    Because they detect the presence of antibodies the body has created to fight against COVID-19 infection, antibody tests have delayed effectiveness after the onset of infection. Since the body only begins producing antibodies at least 7 days after it has been exposed to the virus, antibody tests are only effective when administered after one or two weeks of infection. In comparison, antigen tests detect virus particles, which become readily present in the body after exposure. Thus, antigen testing is suitable for early detection at the beginning stages of infection.

    Antibody tests are valuable for gaining knowledge about how widespread disease antibodies are within a population and whether they provide immunity. However, while they may provide helpful information, antibody tests can only evaluate whether you have previously been infected— not whether you currently are. This is because these tests do not detect the virus itself, therefore, cannot be used for the detection of active infections. Thus, although they play an important role in understanding the spread of the pandemic, antibody tests cannot replace testing for the virus itself. 

  • What is the need for antigen testing in the current stage of the COVID-19 pandemic? 

    Containing the COVID-19 global pandemic will not be a simple task. Life across the world has been upturned, hindered by closed borders, empty schools, and shuttered businesses. In order for us to begin restoring life back to normal, widespread testing is the only surefire method forward.

    What are the challenges to implementing widespread testing that is accessible to everyone? 

    Two of the greatest challenges to making widespread testing possible are the bottlenecks in the laboratories, which are already overwhelmed with the current rate of testing, and insufficient testing materials, resources, and infrastructure. To implement mass testing, we must be able to overcome these constraints. However, relying solely on PCR testing limits our ability to do so.

    To reopen our world once again, we must be able to provide widespread testing that does not rely on time-consuming laboratory processing or expensive equipment. COVID-19 testing needs to be made easy and accessible for everyone. CoVisAg makes this possible by offering simple, fast, and portable testing at any location that delivers rapid, accurate results.

To Order
To purchase CoVisAg or request more information, send us an email at sales@seindabio.com or send us a message.